Biologics for Psoriasis - 23/05/24

Doi : 10.1016/j.det.2024.02.001

Anthony Mitchel Wride, BA, Gloria F. Chen, BA, Sarah L. Spaulding, BS, Elizabeth Tkachenko, MD, Jeffrey M. Cohen, MD ^⁎
Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA

^∗Corresponding author.

Resumen

Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.

El texto completo de este artículo está disponible en PDF.

Keywords : Psoriasis, Biologics, Efficacy, Safety

Esquema

Key points

Introduction

Biologic classes

Tumor Necrosis Factor Alpha Inhibitors

Interleukin-12/23 Inhibitor

Interleukin-23 Inhibitors

Interleukin-17 Inhibitors

Discussion

Highlights of Comorbidities

Comparative Effectiveness

Summary

Clinics care points

Funding Sources: G.F. Chen was supported by a Yale School of Medicine Medical Student Research Fellowship. A.M. Wride and S.L. Spaulding were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, United States under Award Number T35DK104689. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.